The pattern of CD15, CD30 and Bcl-2 expression in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Hematopathology
• Immunohistochemistry

Background:

• Diffuse Large B-cell Lymphoma (DLBCL) is a diverse lymphoid malignancy.
• Immunohistochemical marker expression patterns, including CD15, CD30, and Bcl-2, are not fully characterized in all populations.
• Understanding these markers can aid in DLBCL subtyping and prognosis.

Purpose of the Study:

• To investigate the expression patterns of CD15, CD30, and Bcl-2 in a cohort of DLBCL cases.
• To determine the frequency and significance of these markers in a local population.
• To correlate marker expression with clinical presentation (nodal vs. extranodal).

Main Methods:

• Immunohistochemistry was performed on 67 consecutive DLBCL paraffin-embedded tissue samples.
• Expression of CD15, CD30, and Bcl-2 proteins was evaluated.
• Demographic and clinical data, including presentation site, were analyzed.

Main Results:

• CD15 expression was infrequent, observed in only 3 out of 67 cases.
• CD30 expression was also rare, with weak membrane staining in 3 cases.
• Co-expression of CD15 and CD30 was exceptionally rare.
• Bcl-2 protein was expressed in 64% (43/67) of DLBCL cases, more often in nodal than extranodal tumors.

Conclusions:

• CD15 and CD30 expression are uncommon in DLBCL.
• Co-expression of CD15 and CD30 is rare in DLBCL.
• Bcl-2 protein expression is a frequent finding in DLBCL, especially in nodal disease.